CUPR vs HROW vs PAHC vs ELAN vs ZTS

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -52. 0% for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR). Zoetis Inc. (ZTS) offers the better valuation at 14. 5x trailing P/E (12. 4x forward), making it the more compelling value choice. Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 14. 5x versus Phibro Animal Health Corporation at 36. 3x. On forward P/E, Zoetis Inc. is actually cheaper at 12. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 1. 04x versus Phibro Animal Health Corporation's 1. 90x — a reasonable growth-adjusted valuation.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -93. 6% for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR). Over 10 years, the gap is even starker: HROW returned +914. 3% versus CUPR's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) is the lower-risk stock at 0.

02β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 8445% more volatile than CUPR relative to the S&P 500. On balance sheet safety, Elanco Animal Health Incorporated (ELAN) carries a lower debt/equity ratio of 61% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus -52. 0% for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus -32. 3% for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus -34. 0% for CUPR. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 1. 04x versus Phibro Animal Health Corporation's 1. 90x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zoetis Inc. (ZTS) trades at 12. 4x forward P/E versus 82. 9x for Harrow Health, Inc. — 70. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.

In this comparison, ZTS (2.

3% yield), PAHC (1. 1% yield) pay a dividend. CUPR, HROW, ELAN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

02)). Both have compounded well over 10 years (CUPR: -93. 6%, ELAN: -33. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CUPR is a small-cap quality compounder stock; HROW is a small-cap high-growth stock; PAHC is a small-cap high-growth stock; ELAN is a mid-cap quality compounder stock; ZTS is a mid-cap deep-value stock. PAHC, ZTS pay a dividend while CUPR, HROW, ELAN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.